(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3... March 10 AutoGenomics, a leader in,developing au...ay that it,will be among the leading healthcare an...nnual Cowen Health Care Conference that will be he...Massachusetts. Fareed Kureshy,President and Chief ...company, its automated molecular testing platform ...
...sed on data previously reported, communicated in l...DGEWATER, N.J., March 7 Ortho Biotech Products, L...CRIT(R) (Epoetin alfa),following guidance from the... labeling for all drugs within the erythropoiesis-...the label were based on an unplanned interim analy...
...E, Ind. - The National Nuclear Security Administra...nt for a research center at Purdue University,s Di...ommercial and defense applications, Purdue officia...focus on the behavior and reliability of miniature...ence chosen by the NNSA. , About 35 researchers a...
Other Biology Technology:Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7Purdue leads center to simulate behavior of micro-electromechanical systems 2Purdue leads center to simulate behavior of micro-electromechanical systems 3Purdue leads center to simulate behavior of micro-electromechanical systems 4PCASMC (P350-05) from European Collection of Cell Cultures (ECACC)
Rabbit Anti-alpha-N-Catenin Polyclonal Antibody, Unconjugated from Cell Signaling Technology
BioDoc-It System from UVP
AC1 Auto System, OptiChemi™ Camera from UVP
Biology Products: